Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) has announced that members of its leadership team will attend the Planet MicroCap Toronto Investment Conference on October 27, 28, and 29 at the Arcadian Loft, 401 Bay Street. The company, a developer of Physical AI systems for the pharmaceutical and high-value chemical industries, will hold one-on-one meetings with investors, analysts, and industry participants. The appearance offers investors a direct opportunity to assess Telescope's commercial progress following three Self-Driving Laboratory deployments in its 2026 fiscal year.

Key Points

  • Telescope Innovations Corp. (CSE: TELI) is a Vancouver-based developer of Physical AI and Self-Driving Laboratory systems for the pharmaceutical and chemical sectors.
  • CEO Henry Dubina will present on Wednesday, October 28, from 4:00–4:30 p.m. and will conduct one-on-one investor meetings on Thursday, October 29.
  • Three SDL engagements were completed in fiscal 2026: installations at KPBMA (South Korea), Pfizer, and a major global pharmaceutical company's European operations.
  • Investors may watch for updates on SDL deployments and the company's DirectInject-LC™ technology discussed at the conference.

Three Self-Driving Lab Deployments Underpin Telescope's 2026 Conference Pitch

Telescope arrives at the Toronto conference with a notable commercial track record in its 2026 fiscal year. The company installed Korea's first pharmaceutical Self-Driving Laboratory at the Korea Pharmaceutical and Biopharma Manufacturer's Association in December 2025, followed by a second SDL at Pfizer in February 2026 under a Master Collaborative Research Agreement. A third SDL agreement was signed with a major global pharmaceutical company for its European operations in June 2026. These milestones form the basis of the company's investor discussions at the conference, according to the release.

CEO Henry Dubina to Lead Presentation and One-on-One Investor Meetings

Chief Executive Officer Henry Dubina will personally host Telescope's formal presentation on Wednesday, October 28, from 4:00 to 4:30 p.m., with a question-and-answer period for attendees. Dubina is also scheduled to conduct a series of one-on-one meetings on Thursday, October 29. Management will be available to discuss SDL deployments, the company's DirectInject-LC™ reaction sampling technology, and Telescope's broader growth strategy, the announcement states.

DirectInject-LC™ Technology and Global Commercial Reach in Focus

Alongside its SDL platform, Telescope manufactures the DirectInject-LC™ reaction sampling system and offers contract process development services. The company's platforms combine robotics, real-time analytics, and artificial intelligence to conduct chemistry experiments with greater speed and consistency than manual methods. Clients span bio-pharmaceutical, specialty chemical, and advanced materials sectors. The release states commercial deployments now span North America, Europe, and Asia, positioning the company as a globally active Physical AI developer ahead of its Toronto investor engagement.